Scientific conference in universities or research centers (Scientific conferences in universities or research centers)
GBS EPIDEMIOLOGY & VACCINE NEED IN DEVELOPED COUNTRIES
Melin, Pierrette
2012
 

Files


Full Text
MELIN JVAC_14236_published 2013 august 28.pdf
Publisher postprint (1.41 MB)
Paper published after the symposium
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Group B streptococcus; Vaccine; Prevention; neonatal disease; epidemiology; screening
Abstract :
[en] Development of a group B streptococcal vaccine (GBS) vaccine is the most promising approach for the prevention of GBS infections in babies, given the potential adverse effects of intrapartum antibiotic prophylaxis as well as the need for effective prevention of both adult and late perinatal disease. There are numerous prevention strategies at this time but none are 100% effective in the eradication of neonatal early onset GBS disease and there are no preventative strategies for late onset disease. The need for a GBS vaccine is therefore, of utmost importance. Efforts applying genomics to GBS vaccine development have led to the identification of novel vaccine candidates. The publication of GBS whole genomes coupled with new technologies including multigenome screening and bioinformatics has also allowed researchers to overcome the serotype limitation of earlier vaccine preparations in the search of a universal effective vac- cine against GBS. This review brings together the key arguments concerning the potential need of a GBS vaccine in developed countries and describes the current status with GBS epidemiology and microbiology in these countries
Research center :
Novartis Vaccines Research Center, Siena, Italy
Disciplines :
Immunology & infectious disease
Author, co-author :
Melin, Pierrette  ;  Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Bactériologie, mycologie, parasitologie, virologie
Language :
English
Title :
GBS EPIDEMIOLOGY & VACCINE NEED IN DEVELOPED COUNTRIES
Publication date :
06 July 2012
Event name :
Prevention of perinatal Group B streptococcal disease through maternal immunization
Event organizer :
Novartis vaccine
Event place :
Siena, Italy
Event date :
6 juillet 2012
Audience :
International
Commentary :
Group B streptococcus (GBS) is a leading cause of bacterial meningitis and sepsis during the first three months of life. The incidence of infection ranges between 0.6 and 3 cases per 1000 newborns and mortality rates vary from 5% to greater than 30% depending on geographic location. The presence of antibodies against capsular polysaccharides in the mothers reduces the risk of newborn infection. How vaccination of pregnant women with conjugate vaccines can prevent GBS disease in infants will be the focus of the meeting. Symposium + Working group Co-chair of the working group "GBS Epidemiology & Vaccine Need in Developed Countries"
Available on ORBi :
since 23 February 2014

Statistics


Number of views
46 (0 by ULiège)
Number of downloads
179 (2 by ULiège)

Bibliography


Similar publications



Contact ORBi